Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: A randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study)Francisco Hernández‐Bernal, Verena L. Muzio‐González, Maria C. Ricardo-Cobas et al.|EClinicalMedicine|2022Cited by 69
An engineered SARS-CoV-2 receptor-binding domain produced in Pichia pastoris as a candidate vaccine antigenMiladys Limonta‐Fernández, Gerardo Guillén, Mónica Béquet‐Romero et al.|New Biotechnology|2022Cited by 58
A recombinant SARS-CoV-2 receptor-binding domain expressed in an engineered fungal strain of Thermothelomyces heterothallica induces a functional immune response in miceLaura Lazo, Gerardo Guillén, Mónica Béquet‐Romero et al.|Vaccine|2022Cited by 21
The SARS-CoV-2 receptor-binding domain expressed in Pichia pastoris as a candidate vaccine antigenMiladys Limonta‐Fernández, Gerardo Guillén, Glay Chinea-Santiago et al.|medRxiv|2021Cited by 19
HeberNasvac, a Therapeutic Vaccine for Chronic Hepatitis B, Stimulates Local and Systemic Markers of Innate Immunity: Potential Use in SARS-CoV-2 Postexposure ProphylaxisVerena Muzio, Jorge Aguiar, Gerardo García et al.|Euroasian Journal of Hepato-Gastroenterology|2021Cited by 12